Caxton Associates (New York) Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$67.4M |
| 2 |
Pfizer
PFE
|
+$65.6M |
| 3 |
Aptiv
APTV
|
+$29.7M |
| 4 |
Moderna
MRNA
|
+$22.6M |
| 5 |
Salesforce
CRM
|
+$19.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baidu
BIDU
|
+$85.2M |
| 2 |
Sunrun
RUN
|
+$64.1M |
| 3 |
TPIC
TPI Composites
TPIC
|
+$31.4M |
| 4 |
Microsoft
MSFT
|
+$30.9M |
| 5 |
Amazon
AMZN
|
+$30.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 28.6% |
| 2 | Miscellaneous | 25.49% |
| 3 | Healthcare | 14.26% |
| 4 | Technology | 11.37% |
| 5 | Financials | 4.51% |
Similar funds
Caxton Associates (New York)'s Q3 2021 Portfolio in Review
As of Q3 2021, Caxton Associates (New York) held 657 positions worth $905M, down 0.73% from $912M the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Caxton Associates (New York) withdrew a net $49M in Q3 2021, closing 223 positions and reducing 86 holdings. Its most notable exit was Baidu, an estimated $85.2M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 29% of assets, up from 20% a quarter earlier, followed by Miscellaneous and Healthcare.
Against the trend, Caxton Associates (New York) opened a new position in Pfizer worth $63.7M.
- Caxton Associates (New York)'s largest Q3 2021 buy was Pfizer: 1,480,000 shares worth $63.7M.
- Caxton Associates (New York) added most to Tesla in Q3 2021, an estimated $67.4M increase.
- Caxton Associates (New York)'s biggest Q3 2021 reduction was Sunrun, cutting an estimated $64.1M.
- Caxton Associates (New York) fully exited Baidu in Q3 2021, selling an estimated $85.2M.
- Caxton Associates (New York)'s ten largest holdings make up 52% of its $905M portfolio in Q3 2021.
- Caxton Associates (New York) opened 198 new positions and closed 223 in Q3 2021.
- Caxton Associates (New York)'s portfolio value fell 0.73% quarter-over-quarter to $905M.
Based on Caxton Associates (New York)'s 13F filing for Q3 2021, filed 15 Nov 2021.